Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schumer Wants To Up Pharma Reform Ante To $106 Bil. Via Medicare Rebates

Executive Summary

Sen. Chuck Schumer is looking to revive the idea of getting more savings from the pharmaceutical industry than the $80 billion already pledged toward health reform and is eyeing Senate floor debate as the venue

You may also be interested in...

Part D Rebates: Defeat In Finance Committee May Set Key Precedent

Democratic Sen. Bill Nelson of Florida may have made a tactical error in bringing up an amendment to mandate drug rebates under Medicare Part D during the Senate Finance Committee's markup of health reform legislation

Pharma's Reform Bounce: How Big A Boost Will $80 Bil. Buy

The introduction of the Senate Finance Committee's health care proposal turns the focus from what the pharmaceutical industry will contribute to reform efforts toward what manufacturers stand to gain

Getting To $80 Bil.: PhRMA Expects Mix Of Rebates And Fees In Finance Bill

The Pharmaceutical Research and Manufacturers of America is expecting to make good on its pledge to contribute $80 billion to health care reform through a combination of drug rebates and fees, in addition to savings from follow-on biologics and the previously announced 50 percent discount on drugs used in the Medicare Part D donut hole

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts